Diosgenin Suppresses Cholangiocarcinoma Cells via Inducing Cell Cycle Arrest and Mitochondria-mediat

来源 :2019中国肿瘤学大会 | 被引量 : 0次 | 上传用户：yizeswing

【摘要】

：

Objective Cholangiocarcinoma(CCA)is one of the common malignant tumors.Its typical features include serious drug resistance and poor prognosis.

【作者】

：

Xiao Mei Mao Pan Zhou Xiao Yun Zhang Si Yang Li Jin Xing Shen Qing Xi Chen Jiang Xing Zhuang Dong Yan Shen

【机构】

：

Biobank,The First Affiliated Hospital,School of Medicine,Xiamen University;School of Life Sciences,X

【出处】

：

2019中国肿瘤学大会

【发表日期】

：

2019年7期

【关键词】

：

Diosgenin cholangiocarcinoma apoptosis mitochondria GSK3β/β-catenin pathway

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　Objective Cholangiocarcinoma(CCA)is one of the common malignant tumors.Its typical features include serious drug resistance and poor prognosis.

其他文献

Apatinib inhibits cell proliferation and induces autophagy via the PI3K/Akt signaling pathway in hum

Objective Objective: PTC is the most common type of thyroid cancer and has a favorable prognosis.However,patients with metastatic radioiodine-refractory papillary thyroid carcinoma(PTC)have limited op

会议

Apatinibpapillary thyroid carcinomaapoptosisautophagy

Saracatinib抑制EGFRvⅢ阳性胶质瘤干细胞“干性”特征的实验研究

目的 EGFRvⅢ 是胶质母细胞瘤中最常见的突变，具有促进胶质母细胞瘤进展的多种活性。本研究旨在通过体内、外实验揭示SRC 家族激酶抑制剂Saracatinib 对EGFRvⅢ 阳性胶质瘤干细胞的抑制作用。

会议

EGFRvⅢSaracatinib胶质瘤干细胞SRC

PAK1小分子抑制剂AK963抑制人胃癌细胞增殖迁移及机制研究

目的胃癌是我国最常见的恶性肿瘤,在我国其发病率和死亡率居各类肿瘤的首位,因此,寻找胃癌的治疗靶点是当前肿瘤研究领域的热点.P21 活化蛋白激酶1(p21-activated kinase 1,PAK1)作为I 类PAK 家族的代表,是进化上保守的丝氨酸/苏氨酸蛋白激酶,在肿瘤细胞信号转导过程中具有枢纽作用,因此已成为有效的肿瘤治疗靶点.但目前针对该靶点抑制剂的研究正处于起步阶段.

会议

P21活化激酶1抑制剂胃癌增殖迁移

Nek2B activates the wnt pathway and promotes triplenegative breast cancer chemotherapy-resistance by

Objective The molecular mechanism of chemotherapy-resistance in triple-negative breast cancer(TNBC)is unclear.Centrosomal kinase Nek2B is the only Nek2 isomer through the whole process of mitosis.Our

会议

β-cateninWnt signaling pathwayTriple-negative breast cancerChemotherapy resis

靶向vegf/vegfr2基因siRNA对小鼠B16F10移植瘤生长的影响

目的血管内皮生长因子(vascular endothelial growth factor,VEGF)是目前已知的最重要的血管生成调节因子,VEGF 与其受体(vascular endothelial growth factor receptor,VEGFR)特异性结合,调节着血管及肿瘤血管的生成。本研究靶向vegf 及其受体vegfr2 基因 siRNA 对小鼠黑色素瘤细胞B16F10 移植瘤

会议

血管内皮生长因子血管内皮生长因子受体2RNA干扰B16F10移植瘤

Mifepristone Derivative FZU-00,003 Suppresses Triplenegative Breast Cancer Cell Growth partially via

Objective Triple-negative breast cancer(TNBC)is one of the most malignant breast cancers lacking targeted therapeutics currently due to the heterogeneity of the disease,the absence of well-defined mol

会议

FZU-00003KLF5breast cancerMIF derivatives

Artesunate exhibits synergistic anti-cancer effects with cisplatin on lung cancer A549 cells by inhi

Objective Artesunate(ART)has been used extensively as anti-malarial drugs worldwide.Besids,it has also been reported to have anti-cancer activities.However,few studies have investigated the exact anti

会议

ArtesunateCisplatinLung cancerSynergisticProliferationApoptosis

Survivals in Advanced EGFR-Mutant NSCLC Patients Treated with First-Generation EGFR TKIs followed by

会议

advanced NSCLCEGFR TKIsosimertinib

溶瘤病毒OH2激活NK细胞治疗恶性胸腹水的分子机制研究

目的肿瘤是一类严重危害人类健康的疾病。我国近几年癌症发病率逐年增加，恶性程度也越来越高，传统的肿瘤治疗方法存在毒副作用大、易产生耐药性等缺点。

会议

溶瘤病毒OH2恶性胸腹水NK细胞

Identification of an Integrin α6-Targeted Peptide for Nasopharyngeal Carcinoma-Specific Nanotherapeu

会议

Targeted peptideintegrin α 6cancer-targeted therapynanomedicinesnasopharynge

Diosgenin Suppresses Cholangiocarcinoma Cells via Inducing Cell Cycle Arrest and Mitochondria-mediat

与本文相关的学术论文